| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195
Warfarin, a coumarin anticoagulant, is used worldwide for the treatment and prevention of thromboembolic disease. Warfarin therapy, however, can be difficult to manage because of the drug’s narrow therapeutic index and the wide interindividual variability in patient response. It is now clear that genetic polymorphisms in genes influencing metabolism (CYP2C9) and pharmacodynamic response (VKORC1) are strongly associated with warfarin responsiveness. Optimal warfarin dosing in turn drives other positive anticoagulation–related outcomes. Therefore, a strong basic science argument is emerging for prospective genotyping of warfarin patients. Effective clinical translation would establish warfarin pharmacogenomics as a heuristic model for personalized medicine.
This article has been cited by other articles:
|
|
 |
|
  B. H. Rovin, A. M. McKinley, and D. J. Birmingham Can We Personalize Treatment for Kidney Diseases? Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Smith Chiral Toxicology: It's the Same Thing...Only Different Toxicol. Sci., July 1, 2009; 110(1): 4 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. McDonald, M. J. Rieder, M. Nakano, C. K. Hsia, and A. E. Rettie CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant Mol. Pharmacol., June 1, 2009; 75(6): 1337 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Murphy The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008 Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wang, H. Chen, K. M. Momary, L. H. Cavallari, J. A. Johnson, and W. Sadee Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement Blood, August 15, 2008; 112(4): 1013 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Cooper, J. A. Johnson, T. Y. Langaee, H. Feng, I. B. Stanaway, U. I. Schwarz, M. D. Ritchie, C. M. Stein, D. M. Roden, J. D. Smith, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose Blood, August 15, 2008; 112(4): 1022 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zielinska, C. F. Lichti, S. Bratton, N. C. Mitchell, A. Gallus-Zawada, V.-H. Le, M. Finel, G. P. Miller, A. Radominska-Pandya, and J. H. Moran Glucuronidation of Monohydroxylated Warfarin Metabolites by Human Liver Microsomes and Human Recombinant UDP-Glucuronosyltransferases J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 139 - 148. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |
